

# Transforming Patients' Lives

## Janssen Pharmaceutical Companies of Johnson & Johnson

Dedicated to addressing and solving some of the most important needs of our time in oncology, immunology, neuroscience, infectious diseases, vaccines, cardiovascular and metabolic diseases



**12**

Consecutive quarters of operational growth in the pharmaceutical segment

**11** new product launches since 2009



### **FASTEST**

Growing top 10 pharmaceutical company in U.S., Japan & Europe

SOURCE: IMS HEALTH

### Janssen Momentum

- Robust commercial and launch capabilities
- Growing market share
- Ensuring greater access to our medicines
- Strengthening presence in critical geographies
- Nearly doubled our footprint in emerging markets over the last five years

### Extending Global Reach



Emerging markets including China, Brazil, Russia and India comprise nearly 20% of worldwide pharmaceutical sales in the first quarter of 2013.

### Industry Leading Drug Pipeline

Approach to innovation has resulted in a revitalized product portfolio and an industry-leading pipeline of near- and long-term compounds in the areas of Cardiovascular and Metabolic disorders, Immunology, Infectious Diseases and Vaccines, Neuroscience and Oncology

**>10**

Potential NMEs (New Molecular Entities) anticipated to be filed by 2017. NMEs are newly discovered and developed drugs, medicines or therapies

**>25**

More than 25 significant brand line extensions anticipated by 2017

### Transformational Medical Innovation

Late stage products that are planned to be filed by 2017 are aimed at addressing serious unmet needs including:

- Hepatitis C
- Hematologic malignancies
- Rheumatoid Arthritis
- New vaccines to treat influenza, rabies and polio

### Well Prepared for Next Wave of Growth:

- Committed to addressing major unmet medical needs
- Unique model of innovation
- Five Johnson & Johnson global innovation centers

This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation; changes to government laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; complex global supply chains with increasing regulatory requirements; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at [www.sec.gov](http://www.sec.gov), [www.investor.jnj.com](http://www.investor.jnj.com) or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statements as a result of new information or future events or developments.